Halozyme Therapeutics Retained Earnings (Accumulated Deficit) 2010-2025 | HALO
Halozyme Therapeutics retained earnings (accumulated deficit) for the quarter ending March 31, 2025 were $0.478B, a 185.57% increase year-over-year.
- Halozyme Therapeutics retained earnings (accumulated deficit) for 2024 were $0.36B, a 297.43% increase from 2023.
- Halozyme Therapeutics retained earnings (accumulated deficit) for 2023 were $0.091B, a 36.77% decline from 2022.
- Halozyme Therapeutics retained earnings (accumulated deficit) for 2022 were $0.143B, a 343.1% decline from 2021.